Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$58.66
pos +0.00
+0.00%
Today's Range: 58.27 - 59.20 | MRK Avg Daily Volume: 8,740,200
Last Update: 07/29/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 11.06%
Open: $0.00
Previous Close: $58.43
52 Week Range: $45.69 - $60.07
Oustanding Shares: 2,768,025,348
Market Cap: 161,735,721,084
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 5 5 5
Moderate Buy 0 0 0 0
Hold 8 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.33 2.17 2.17 2.17
Latest Dividend: 0.46
Latest Dividend Yield: 3.15%
Dividend Ex-Date: 09/13/16
Price Earnings Ratio: 35.85
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
35.85 36.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.97% 0.21% 21.35%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.20 -0.06
Net Income -62.60 -0.30 -0.11
EPS -61.70 -0.20 -0.08
Earnings for MRK:
EBITDA 13.92B
Revenue 39.50B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.92 $0.98 $3.72 $3.71
Number of Analysts 9 5 10 10
High Estimate $0.94 $1.00 $3.77 $3.94
Low Estimate $0.90 $0.95 $3.67 $3.33
Prior Year $0.86 $0.96 $3.59 $3.72
Growth Rate (Year over Year) 6.72% 1.67% 3.62% -0.19%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Jul 29, 2016 | 12:28 PM EDT
The stock is back to an area where sellers could emerge.
By

David Katz

 | Jul 27, 2016 | 7:00 AM EDT

It's too cheap for a biotech giant with years of patent protection for its key products and great cash flow.

bearishMerck downgraded at BMO

Jul 18, 2016 | 7:45 AM EDT
MRK was downgraded from Outperform to Market Perform, BMO Capital said. Valuation call, based on a $62 price target.
By

Jim Cramer

 | Jul 18, 2016 | 6:00 AM EDT
Let me give you the unassailable themes.
By

Jim Cramer

 | Jul 13, 2016 | 7:18 AM EDT
I care about making and preserving my clients' money.
By

Bret Jensen

 | Jul 8, 2016 | 1:00 PM EDT
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
By

Jim Cramer

 | Jun 16, 2016 | 11:10 AM EDT
The market will 'continue to be rough' for investors with lower oil and Brexit worries weighing on investors minds, says TheStreet's Jim Cramer.
By

Jim Cramer

 | Jun 16, 2016 | 10:59 AM EDT
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Merck's stock.
By

Bret Jensen

 | Jun 12, 2016 | 2:00 PM EDT

Both have good capital appreciation potential.

By

Bret Jensen

 | Jun 10, 2016 | 10:00 AM EDT

Both have good capital appreciation potential.

Market continues to be mixed.  Oil having a rare up day of late, but still up less th...
My colleague Suz Smith (RM contributor) often talk about different trade scenarios and str...
Thursday's Philadelphia Inquirer reported that the average requested increase for individu...
Markets set to open slightly lower as second quarter GDP comes in at a much lower than exp...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.